Undervalued R&D Leader with a 6% Yield

Declining R&D productivity and rising costs are driving bio-pharma firms to increase the use of Contract Research Organizations (CROs). CROs represent a growing healthcare niche that benefits from significant barriers to entry and the trend towards outsourced R&D. Among public companies in the CRO space, this one earns our Very Attractive rating and leads the group in return on invested capital (ROIC), the key driver of shareholder value.

Not a Member Yet?

You need a Gold Membership or higher to view the content on this page.
Start Your Gold Membership Today | Members Log In Here

Photo Credit: Nick Ares (Flickr)

Leave A Response

* Denotes Required Field